Dr. Brooke Daniel, M.D.
Claim this profileTennessee Oncology - Chattanooga Oncology & Hematology Associates
Studies Breast Cancer
Studies PD-L1 Negative
9 reported clinical trials
16 drugs studied
Area of expertise
1Breast Cancer
Stage IV
Stage III
HER2 negative
2PD-L1 Negative
Stage IV
ER negative
PR negative
Affiliated Hospitals
Clinical Trials Brooke Daniel, M.D. is currently running
Lasofoxifene and Abemaciclib vs Fulvestrant and Abemaciclib
for Breast Cancer
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.
Recruiting2 awards Phase 312 criteria
ARX788
for HER2-Positive Breast Cancer
This trial tests ARX788, a new IV medicine, for patients with HER2-positive metastatic breast cancer who did not respond well to T-DXd. The medicine targets a specific protein on cancer cells to help stop their growth.
Recruiting1 award Phase 28 criteria
More about Brooke Daniel, M.D.
Clinical Trial Related1 year of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Brooke Daniel, M.D. has experience with
- Abemaciclib
- Fulvestrant
- ARX788
- Tucatinib
- Trastuzumab Deruxtecan
- Pembrolizumab
Breakdown of trials Brooke Daniel, M.D. has run
Breast Cancer
Colorectal Cancer
Endometrial Cancer
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Brooke Daniel, M.D. specialize in?
Brooke Daniel, M.D. focuses on Breast Cancer and PD-L1 Negative. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are Stage III.
Is Brooke Daniel, M.D. currently recruiting for clinical trials?
Yes, Brooke Daniel, M.D. is currently recruiting for 3 clinical trials in Chattanooga Tennessee. If you're interested in participating, you should apply.
Are there any treatments that Brooke Daniel, M.D. has studied deeply?
Yes, Brooke Daniel, M.D. has studied treatments such as Abemaciclib, Fulvestrant, ARX788.
What is the best way to schedule an appointment with Brooke Daniel, M.D.?
Apply for one of the trials that Brooke Daniel, M.D. is conducting.
What is the office address of Brooke Daniel, M.D.?
The office of Brooke Daniel, M.D. is located at: Tennessee Oncology - Chattanooga Oncology & Hematology Associates, Chattanooga, Tennessee 37404 United States. This is the address for their practice at the Tennessee Oncology - Chattanooga Oncology & Hematology Associates.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.